Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses using radioimmunotherapy as a treatment option for patients with AML.
Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses using radioimmunotherapy as a treatment option for patients with AML.
Clinical Pearls
Only 40% of patients with AML under the age of 60 are cured while only 10% of patients over the age of 60 are cured. The median survival is approximately 6 months.
Radioimmunotherapy is one way that physicians can help develop more effective therapies while reducing toxicity.
Initial studies used a beta-emitter but now physicians use alpha particles in therapy.
By using alpha particles, physicians are able to target the tumor cell and do less damage to the surrounding normal tissue.
